Explore

Rapid Read Rapid Read
Phase 3 Trial for H5N1 mRNA Vaccine Underway Amid Pandemic Preparedness Efforts

Phase 3 Trial for H5N1 mRNA Vaccine Underway Amid Pandemic Preparedness Efforts

A phase 3 clinical trial is in progress to evaluate the effectiveness of an mRNA vaccine for H5N1, a strain of influenza with pandemic potential. The virus, primarily found in birds, poses a significant threat if it mutates to spread easily among humans. The trial aims to develop a vaccine that can be rapidly deployed in the event of an outbreak. This initiative is part of broader efforts to enhance global preparedness following the COVID-19 pandemic. John Tregoning, a Professor of Vaccine Immunology, highlights the potential of mRNA vaccines to revolutionize pandemic response strategies.
AP News AP News
Tick season seems to be off to a fast start, and some expert worry about future illnesses

Tick season seems to be off to a fast start, and some expert worry about future illnesses

Tick season seems to be off to a fast start, with an unusually high number of bites already reported across the country
AP News AP News
Tick season seems to be off to a fast start, and some experts worry about future illnesses

Tick season seems to be off to a fast start, and some experts worry about future illnesses

Tick season seems to be off to a fast start, with an unusually high number of bites already reported across the country
Rapid Read Rapid Read
WHO's Big Catch-Up Initiative Delivers Over 100 Million Childhood Vaccinations Amid COVID-19 Disruptions

WHO's Big Catch-Up Initiative Delivers Over 100 Million Childhood Vaccinations Amid COVID-19 Disruptions

The World Health Organization (WHO), in collaboration with Gavi, the Vaccine Alliance, and UNICEF, has successfully delivered over 100 million vaccine doses to approximately 18.3 million children across 36 countries through the Big Catch-Up initiative. Launched during World Immunization Week 2023, this effort aimed to address the decline in vaccination rates caused by the COVID-19 pandemic. The initiative targeted 'zero-dose children' who had not received any vaccines and those who had missed measles vaccinations. The program concluded in March 2026 and is on track to meet its goal of reaching 21 million children. Despite this success, WHO and its partners emphasize the need for sustainable routine immunization programs to prevent future outbreaks of vaccine-preventable diseases.
Rapid Read Rapid Read
WHO Prequalifies First Malaria Treatment for Infants, Enhancing Global Health Efforts

WHO Prequalifies First Malaria Treatment for Infants, Enhancing Global Health Efforts

The World Health Organization (WHO) has prequalified the first-ever malaria treatment specifically designed for newborns and infants weighing between two and five kilograms. This development marks a significant advancement in addressing malaria in one of the most vulnerable patient groups. The newly prequalified treatment, artemether-lumefantrine, meets international standards of quality, safety, and efficacy, and will help close a long-standing treatment gap for approximately 30 million babies born each year in malaria-endemic areas of Africa. Additionally, WHO has prequalified three new rapid diagnostic tests (RDTs) to address emerging diagnostic challenges, ensuring accurate diagnosis and treatment where traditional tests fail.
Rapid Read Rapid Read
Phase 3 Trial for mRNA Vaccine Targets H5N1 Influenza Preparedness

Phase 3 Trial for mRNA Vaccine Targets H5N1 Influenza Preparedness

A phase 3 clinical trial is underway to test the effectiveness of an mRNA vaccine for the H5N1 influenza strain, a virus primarily found in birds but potentially dangerous to humans. The trial aims to develop a vaccine that could be rapidly deployed in the event of a mutation leading to widespread human transmission. This initiative is part of a broader effort to enhance global preparedness for future pandemics, following the lessons learned from the COVID-19 pandemic. The trial is being closely watched by governments and health organizations worldwide, eager to improve their response capabilities to emerging infectious diseases.
Rapid Read Rapid Read
Moderna Begins Trial of mRNA Vaccine for H5N1 Bird Flu in US and UK

Moderna Begins Trial of mRNA Vaccine for H5N1 Bird Flu in US and UK

Moderna has initiated a pivotal trial for its mRNA-based vaccine targeting the H5N1 bird flu strain, with the trial taking place in both the United States and the United Kingdom. The vaccine, known as mRNA-1018, is designed to combat a new strain of the influenza virus that has significantly impacted bird populations and livestock globally, while also being responsible for hundreds of human fatalities. The trial aims to assess the vaccine's safety and immunogenicity in approximately 4,000 healthy adults aged 18 and older. This development highlights the potential of mRNA technology to revolutionize pandemic responses, building on the success of mRNA vaccines during the COVID-19 pandemic. The trial is particularly focused on recruiting participants from the poultry industry and individuals over 65, who are considered most at risk.
Rapid Read Rapid Read
Silent Measles Spread in US Threatens Elimination Status

Silent Measles Spread in US Threatens Elimination Status

Newer testing methods have revealed a significant silent spread of measles in the United States, particularly in Utah and Arizona, threatening the country's measles elimination status. Reports indicate that measles cases have topped 1,700 in the first four months of the year, with a major outbreak in a community spanning northern Arizona and southern Utah. The outbreak, which has grown to over 600 reported cases, is linked to low vaccination rates and distrust in vaccines within certain communities. The US Centers for Disease Control and Prevention (CDC) is using molecular evidence to trace the origins and true size of the outbreak, which may have started much earlier than initially reported.
Rapid Read Rapid Read
Texas Biomed Launches $2 Million Fund to Boost Tuberculosis Research

Texas Biomed Launches $2 Million Fund to Boost Tuberculosis Research

The Texas Biomedical Research Institute has announced the creation of a $2 million Tuberculosis Innovation and Technology Fund. This fund, supported by philanthropic investments, aims to accelerate research and development of new therapies and cures for tuberculosis (TB), the world's deadliest infectious disease. The fund will support the recruitment of top scientific talent and the acquisition of advanced research technologies, such as the Akoya Phenocycler system and the Emulate Orb and Zoe Culture module system. These tools will enhance the study of TB at a cellular level, facilitating the development of new vaccines and therapeutics. Texas Biomed's initiative is part of a broader effort to combat TB, which remains a significant health concern in Texas and globally.
Rapid Read Rapid Read
Texas Biomed Launches Tuberculosis Innovation Fund to Boost Research and Treatment

Texas Biomed Launches Tuberculosis Innovation Fund to Boost Research and Treatment

Texas Biomedical Research Institute has announced the establishment of a $2 million Tuberculosis Innovation and Technology Fund. This initiative is supported by philanthropic investments aimed at accelerating research and development of new therapies and cures for tuberculosis (TB), the world's deadliest infectious disease. The fund will enhance the institute's ability to recruit top scientific talent and acquire advanced research technologies. These technologies will allow for more detailed studies of disease mechanisms and interactions, potentially leading to breakthroughs in TB prevention and treatment. Texas Biomed's efforts are part of a broader global initiative to combat TB, which remains a significant health concern, particularly in Texas, where TB cases have been rising.
Rapid Read Rapid Read
Texas Biomed Launches $2 Million Fund to Boost Tuberculosis Research and Treatment

Texas Biomed Launches $2 Million Fund to Boost Tuberculosis Research and Treatment

Texas Biomedical Research Institute has announced the establishment of a $2 million Tuberculosis Innovation and Technology Fund. This initiative is supported by philanthropic investments aimed at accelerating research and development of therapies for tuberculosis (TB), the world's deadliest infectious disease. The fund will be used to recruit top scientific talent and acquire advanced research technologies, such as the Akoya Phenocycler system and the Emulate Orb and Zoe Culture module system. These tools will enhance the study of disease mechanisms and aid in the development of new treatments. Texas Biomed, which hosts a premier NIH-funded TB research center, aims to strengthen its capabilities and contribute to global efforts to combat TB, which remains a significant health concern in Texas.
Rapid Read Rapid Read
U.S. Health Officials Halt Publication of COVID-19 Vaccine Effectiveness Study Amid Methodology Dispute

U.S. Health Officials Halt Publication of COVID-19 Vaccine Effectiveness Study Amid Methodology Dispute

U.S. health officials have stopped the publication of a study that evaluated the effectiveness of COVID-19 vaccines in preventing hospitalizations and emergency room visits. The study, which was set to be published in the Centers for Disease Control and Prevention's (CDC) Morbidity and Mortality Weekly Report, concluded that the vaccine reduced ER visits and hospitalizations by about half among healthy adults during the past winter. The decision to halt the publication was confirmed by a U.S. Department of Health and Human Services spokesman, citing concerns over the study's methodology. This methodology, which involves comparing the odds of a positive COVID-19 test among vaccinated and unvaccinated patients, has been used in other reputable journals. However, HHS officials argue that factors such as prior infection and patient behavior could affect the results.